Member Info for beinthelead

All part of the media’s focus on readying PCR’s termination.

Agreed Apre. NED’s are generally head hunted for their network and efficient access to third parties they would not normally have access to.

A sign that the trolls seem to be running out of steam… repetition of the old ‘no sales’ narrative now landing on deaf ears.

First it was ‘saliva failed’
Then, ‘you have no test’
Then, ‘Affimers are not proven’
Then, ‘you have no CE mark’
Then, ‘you have no capacity’

You get the picture…

We have capacity. The best performing LFT. Affimers are proven. AVA6000 in the clinic.

Trolls are clutching at straws. The tide will soon turn.

Be careful - I think he’s reading the board. Like Sticky - hates it, full of morons, beneath him etc. But still reads. Odd, isn’t it?

At least Ndn is consistent on both platforms. I’ll give him that.

Very good, Apre. Couldn’t comment, but he’s certainly got a thing for Avacta.

Scaredy - You’ve got a fan on Twitter that calls himself ‘The Bishop’. Refers to you as a ‘ramper’. Don’t get hurt all at once.

Why on earth do these people spend so much time talking down a stock? They do it with such passion Genuinely have no idea why.

Ophidian - thinking the same thing

*Affimers before the spellcheck police run amok.

Lots of experts out on Twitter at the moment. The Bishop and Sticky (a holder!) doing the noble thing in kicking a stock when it’s down.

Valuations are being linked back to early 20p days when Affimers were held by Avacta. Ask yourself; is it worth more than 20p when have;

£40m in the bank
Affirmers proven in the diagnostics division via AffiDx platform
Multiple licensing deals
AffiDx sales - still unknown quant’s.
In the clinic with AVA6000

Selling AffiDx in huge numbers via HMG vs lower level estimates 2-5m/month is not a case of feast or famine. This is the picture being painted.

My worst case valuation is based on scale up to 5m/month by year end. Best case, HUA and sales via Medusa.

I’d like to take hold less risk going into AVA6000 feedback, but it seems the LFT revenue is close to be running in parallel.

Runner - agreed. The IP, now proven, is worth the MC on it’s own. Awful to see the slippage, but patience will out.

Hindsight police, sticky, new accounts; they’re all out this morning. At the same time.

Even if their efforts aren’t a coordinates, they all have something common. They all want to be correct and feed that Ego. Make your own choices. Selling is always valid for the right reasons. Listening to these guys is certainly not.

Come back tomorrow with a extended list of how bad this investment is, and why it’s a bad hold. Caveat with ‘good luck’ and all is forgiven.

Unreal.

Sticky is telling us we’re going ‘sub £1’ every 5 mins. Things must be bad.

Trek - if you say bye, just leave. Never credible to leave with a few shots before you go.

Additionally, the recent prolonged attacks on Myles are an attempt to remove the last line of comfort for many investors. Have your own views on Myles, but he holds significant credibility with many holders.

Arrogance
Bitterness
Paid to post
Hatred
Egotistical
Jealousy

Some of the worst personality traits.

Thanks Energy.

Key points from: COUNCIL RECOMMENDATION

on a common framework for the use and validation of rapid antigen tests and the mutual recognition of COVID-19 test results in the EU

(2021/C 24/01)

- While cheaper and faster, rapid antigen tests have generally a lower test sensitivity than RT-PCR.

- Under the Regulation, rapid antigen tests will be subject to reinforced requirements on device performance and a thorough assessment by a notified body

- Effective testing contributes to the smooth functioning of the Internal Market as it allows for targeted isolation or quarantine measures

- Have been validated by at least one Member State as being appropriate for their use in the context of COVID-19, providing details on the methodology and results of such studies, such as the sample type used for validation, the setting in which the use of the test was assessed

Zoom - absolutely. Can’t believe people now doubting it.

FTS - Their Visitect test has a pre-filled buffer, I believe. That’s said, it may had one before, I haven’t followed closely.

Morning.

The main operational difference between AffiDx and approved HU tests, appears to be the pre-filled extraction tube.

Acon’s recent use in T&T uses a pre-filled buffer extraction tube.

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1006806/COVID-19-self-test-nose-only-instructions-acon-flowflex-large-print.pdf

AffiDx for pro use, doesn’t.

https://bioservuk.com/wp-content/uploads/2021/06/IFU.pdf

What’s interesting is the datasheet for AffiDx. They do not show the buffer filling step in the IFU overview. So, this is either due to aesthetics, and design licence, or, it indicates how the test could be used outside of pro use.

https://avacta.com/wp-content/uploads/2021/07/Brochure-Type-00901-SC2-Product-Specification-Sheet-v3-ID-33989.pdf

The pre-filled extraction tube is certainly advantageous as it removes a ‘messy’ step in the process. Have you guys got any thoughts?